|
|
||||||||
1 Dept of Pathology, University of British Columbia, Vancouver, Canada. 2 AstraZeneca, Lund, Sweden
CORRESPONDENCE: J.L. Wright, Dept of Pathology, University of British Columbia, Vancouver, British Columbia V6T 2B5, Canada. Fax: 1 6048227104. E-mail: jlwright@interchange.ubc.ca
Keywords: cell proliferation, cigarette smoke, pulmonary hypertension
Received: October 21, 2002
Accepted March 11, 2003
This study was supported by AstraZeneca (Lund, Sweden) research and development and grant MOP42539 from the Canadian Institutes of Health Research.
Cigarette smoking produces pulmonary hypertension (PHT) through unknown mechanisms. In animal models acute smoke exposure induces cell proliferation in the small arteries adjacent to the alveolar ducts, and chronic exposure results in muscularisation of these vessels, with changes related to the development of PHT. Studies indicate that serine-elastase inhibitors can prevent experimental monocrotaline-induced PHT. This study examined whether they could also prevent cigarette smoke-induced pulmonary vascular disease.
Guinea-pigs were exposed to cigarette smoke or air for 6 months. Some animals also received ZD0892, an orally active, synthetic, selective, serine-elastase inhibitor. The percentage of muscularised, small, pulmonary arteries was determined by morphometric analysis of histological sections and vascular cell proliferation by proliferating cell nuclear antigen staining.
Vascular cell proliferation was markedly increased in the smoke-exposed animals and the percentage of completely muscularised small vessels was increased four-fold. Cell proliferation indices correlated with muscularisation indices. In the animals treated with ZD0892, the number of completely muscularised vessels was reduced by 50% and cell proliferation was reduced by 61%.
These data suggest that smoke-induced cell proliferation leads to pulmonary arterial muscularisation. Serine-elastase inhibitors appear to be able to reduce cell proliferation and vascular remodelling.
This article has been cited by other articles:
![]() |
A. Churg, M. Cosio, and J. L. Wright Mechanisms of cigarette smoke-induced COPD: insights from animal models Am J Physiol Lung Cell Mol Physiol, April 1, 2008; 294(4): L612 - L631. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. S. Perlstein and R. T. Lee Smoking, Metalloproteinases, and Vascular Disease Arterioscler. Thromb. Vasc. Biol., February 1, 2006; 26(2): 250 - 256. [Abstract] [Full Text] [PDF] |
||||
![]() |
J L Wright, R D Levy, and A Churg Pulmonary hypertension in chronic obstructive pulmonary disease: current theories of pathogenesis and their implications for treatment Thorax, July 1, 2005; 60(7): 605 - 609. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Buhl and S. G. Farmer Future Directions in the Pharmacologic Therapy of Chronic Obstructive Pulmonary Disease Proceedings of the ATS, April 1, 2005; 2(1): 83 - 93. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. L. Wright, H. Tai, and A. Churg Cigarette Smoke Induces Persisting Increases of Vasoactive Mediators in Pulmonary Arteries Am. J. Respir. Cell Mol. Biol., November 1, 2004; 31(5): 501 - 509. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Churg, R. D. Wang, H. Tai, X. Wang, C. Xie, and J. L. Wright Tumor Necrosis Factor-{alpha} Drives 70% of Cigarette Smoke-induced Emphysema in the Mouse Am. J. Respir. Crit. Care Med., September 1, 2004; 170(5): 492 - 498. [Abstract] [Full Text] [PDF] |
||||
![]() |
H.-K. Jeon, H.-S. Jin, D.-H. Lee, W.-S. Choi, C.-K. Moon, Y. J. Oh, and T. H. Lee Proteome Analysis Associated with Cadmium Adaptation in U937 Cells: IDENTIFICATION OF CALBINDIN-D28k AS A SECONDARY CADMIUM-RESPONSIVE PROTEIN THAT CONFERS RESISTANCE TO CADMIUM-INDUCED APOPTOSIS J. Biol. Chem., July 23, 2004; 279(30): 31575 - 31583. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |